Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

TY - JOUR

T1 - Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective

T2 - A Comprehensive Cost-Utility Analysis

AU - NASHNET

AU - Noureddin, Mazen

AU - Jones, Calum

AU - Alkhouri, Naim

AU - Gomez, Eduardo Vilar

AU - Dieterich, Douglas T.

AU - Rinella, Mary E.

AU - Therapondos, George

AU - Girgrah, Nigel

AU - Mantry, Parvez S.

AU - Sussman, Norman L.

AU - Figueroa Diaz, Viviana

AU - Fuchs, Michael

N1 - Funding Information: Funding This study was supported by NASHNET. The role of NASHNET was to provide support for the economic analysis. The sponsor had no input on the article. Funding Information: The authors thank Eric Mitchell for his help with the revision process and ensuring the accuracy of changes made in the documents. Contributing NASHNET members are as follows: George Therapondos, MBChB, FRCP (Edin), MPH, Nigel Girgrah, MD, PhD, Ochsner Medical Center, New Orleans, Louisiana; Parvez S. Mantry, MD, AGAF, FAASLD, CPE, The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas; Norman L. Sussman, MD, Baylor College of Medicine, Houston, Texas; Viviana Figueroa Diaz, MD, NYU Langone Medical Center, New York, New York; Michael Fuchs, MD, PhD, FAASLD, AGAF, FEBGH, Virginia Commonwealth University, Central Virginia VA HealthCare System, and McGuire Research Institute, Richmond, Virginia; Amreen Dinani, MD, Amon Asgharpour, MD, Icahn School of Medicine at Mount Sinai, New York, New York. Funding This study was supported by NASHNET. The role of NASHNET was to provide support for the economic analysis. The sponsor had no input on the article. Conflicts of interest These authors disclose the following: Mazen Noureddin has been on the advisory board for Gilead, Intercept, Pfizer, Novartis, Allergan, Blade, EchoSens North America, OWL, Terns, Simenes, Zydus, and Abbott; has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus; and is a minor shareholder or has stocks in Anaetos and Viking. Calum Jones is an employee of McCann Health. Naim Alkhouri has served on the advisory board for Allergan, Gilead, Intercept, Pfizer, and Zydus; has served as a speaker for AbbVie, Alexion, Gilead, Intercept, and Simply Speaking; and has received research support from Akero, Albireo, Allergan, Axcella, BI, BMS, Celgene, DSM, Gilead, Galmed, Galectin, Genfit, Enanta, Enyo, Hanmi, Inventiva, Madrigal, Merck, Novartis, Novo Nordisk, Pfizer, Poxel, and Zydus. George Therapondos is a consultant for Boston Scientific; is on the advisory board for Janssen, Intercept, Rebiotix, and The Kinetix group; is a speaker for Intercept and Eisai; and receives research support from Conatus, Cellgene, BMS, Madrigal, and Allergan. Parvez S. Mantry is a speaker and consultant and on the advisory board for Gilead, AbbVie, Intercept, Mallinckrodt, Salix, Sirtex, Eisai, and Shinogi and receives research grants from Gilead, AbbVie, Intercept, Mallinckrodt, Salix, Sirtex, Eisai, Shinogi, Allergan, Genfit, Pfizer, Novartis, Galmed, Merck, and BMS. Norman L. Sussman receives research grants from Alexion and Allergan, is an adjudicator for GMP-O and Genfit, and is a consultant for AbbVie, Gilead, and Incyte. Nigel Girgrah is a speaker for Gilead Sciences and a consultant for The Kinetix Group. Michael Fuchs receives grant support (to institution) from Genfit, Gilead, Novartis, Conatus, Madrigal, Viking, Intercept, Allergan, BMS, AbbVie, Celgene, Genentech, Eisai, H3B, and Galectin; receives royalties from Springer; is a consultant for Second Genome; and is a speaker for Simply Speaking NASH. Amreen Dinani is on the advisory board for Intercept Pharmaceutical and Gilead Sciences, is a speaker for Intercept Pharmaceutical, and is a consultant for Genfit, NASHNET, and Expert Connect. Amon Asgharpour is a consultant for Gilead Sciences, Intercept Pharmaceuticals, SanyalBio, Sterotherapeutics, Berenberg Capital, and Expert Connect. Douglas T. Dieterich is a consultant for Gilead Sciences and Intercept Pharmaceuticals. Mary E. Rinella is a consultant for Intercept Pharmaceuticals, Gilead Sciences, NGM Biopharmaceuticals, Enanta, Immuron, Fractyl, Prociento, Gelesis, Merck, Bristol-Myers Squibb, Metacrine, Viking Therapeutics, Allergan, Cymabay, Boehringer Ingelheim, Genentech, Sagimet Bio, Terns, Siemens, and Novartis; receives independent research grant funding from Novartis; and receives support in kind from Owl.

PY - 2020/11

Y1 - 2020/11

KW - Cirrhosis

KW - Fibrosis

KW - High-risk population

KW - NASH

KW - Screening

UR - https://www.scopus.com/pages/publications/85096189589

UR - https://www.scopus.com/inward/citedby.url?scp=85096189589&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.07.050

DO - 10.1053/j.gastro.2020.07.050

M3 - Short survey

C2 - 32763241

AN - SCOPUS:85096189589

SN - 0016-5085

VL - 159

SP - 1985-1987.e4

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -